Hemab Therapeutics reported a third quarter 2026 net loss of $27.3 million, or $0.58 per share, missing the consensus estimate of $0.51. The company remains pre-revenue as it shifts into a pivotal clinical stage, primarily focused on initiating its first Phase 3 trial. Management reported a robust cash position of $430.2 million, which is projected to fund operations into 2029.

Key Highlights

  • Research and development expenses surged to $24.6 million from $14.6 million in the prior year, driven by the launch of the SOLARA Phase 3 study and the HMB-003 Phase 1 trial.
  • Initial clinical data for sutacimig in Factor VII deficiency showed that a single subcutaneous dose shortened prothrombin time by more than 50% in the first two participants.
  • The company dosed the first participant in its Phase 1 trial of HMB-003 for heavy menstrual bleeding, with initial clinical data expected in mid-2027.